Updates on thrombotic events associated with multiple myeloma

References

• Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012;17(Suppl 1):S177–S180.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009;27:4848–4857.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40:338–347.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:437–444.
   PubMedGoogle Scholar
• Kristinsson SY, Pfeiffer RM, Bjorkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991–4998.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582–3586.
   PubMed Web of Science ®Google Scholar
• Fotiou D, Sergentanis TN, Papageorgiou L, et al. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018;8:102.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Bjorkholm M, et al. Thrombosis is associated with inferior survival in multiple myeloma. Haematologica. 2012;97:1603–1607.
   PubMed Web of Science ®Google Scholar
• Schoen MW, Luo S, Gage B, et al. Association of venous thromboembolism with increased mortality in patients with multiple myeloma. J clin oncol. 2018;36:8051.
   Web of Science ®Google Scholar
• Huang H, Li H, Li D. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagul Fibrinolysis. 2015;26:555–559.
   PubMed Web of Science ®Google Scholar
• Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc. 2013;55:75–83.
   PubMed Web of Science ®Google Scholar
• Crowley MP, Eustace JA, O‘Shea SI, et al. Venous thromboembolism in patients with myeloma: incidence and risk factors in a “real-world” population. Clin Appl Thromb Hemost. 2014;20:600–606.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587–600.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254–1266.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–1585.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25:749–760.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986–993.
   PubMed Web of Science ®Google Scholar
• Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933–939.
   PubMed Web of Science ®Google Scholar
• Fotiou D, Gerotziafas G, Kastritis E, et al. A review of the venous thrombotic issues associated with multiple myeloma. Expert Rev Hematol. 2016;9:695–706.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Cancer-Associated Venous Thromboembolic Disease.: National Comprehensive Cancer Network; 2016 Jul 22. Updated Version 1. 2016. Available from: www.nccn.org/professionals/physician_gls/pdf/vte.pdf
   Google Scholar
• Baker HA, Brown AR, Mahnken JD, et al. Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. Cancer Med. 2019;8(1):455-462.
   PubMed Web of Science ®Google Scholar
• Paludo J, Mikhael JR, LaPlant BR, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017;130:1198–1204.
   PubMed Web of Science ®Google Scholar
• Bradbury C. Thrombotic events in patients with myeloma treated with immunomodulatory drugs; results of the myeloma XI study. Blood. 2017;130:553.
   Google Scholar
• Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29:2099–2103.
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:653–663.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Cini M, Zamagni E, Valdre L, et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol. 2010;84:484–492.
   PubMed Web of Science ®Google Scholar
• Fouquet G, Tardy S, Demarquette H, et al. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer. 2013;119:3680–3686.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Swern AS, Li JS, et al. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 2014;4:e257.
   PubMed Web of Science ®Google Scholar
• Rosovsky R, Hong F, Tocco D, et al. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013;160:351–358.
   PubMed Web of Science ®Google Scholar
• Leebeek FW, Kruip MJ, Sonneveld P. Risk and management of thrombosis in multiple myeloma. Thromb Res. 2012;129(Suppl 1):S88–S92.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116:5838–5841.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delforge M, Hajek R, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98:784–788.
   PubMed Web of Science ®Google Scholar
• Stewart AK. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Future Oncol. 2015;11:2121–2136.
   PubMed Web of Science ®Google Scholar
• Hanaizi Z, Flores B, Hemmings R, et al. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2015;20:329–334.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826–1832.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood. 2013;121:1968–1975.
   PubMed Web of Science ®Google Scholar
• Bradbury CJ, Striha M, Striha A, et al. Thrombotic events in patients with myeloma treated with immunomodulatory drgus; results of the myeloma XI study. Blood. 2017;130:553.
   Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–4907.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7:291–292.
   PubMed Web of Science ®Google Scholar
• Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist. 2017;22:1222–1231.
   PubMed Web of Science ®Google Scholar
• Sanfilippo KMW, Wang T, Luo S, et al. Prediction of venous thromboembolism (VTE) in multiple myeloma (MM): Myeloma Clot Score (MCS). Journal of Clinical Oncology. 2018;36:6585.
   Google Scholar
• Sanfilippo KML, Luo S, Wang T, et al. Predicting risk of venous thromboembolism in multiple myeloma: the impede VTE score. In: editor. Blood. San Diego: ASH; 2018. p. 141.
   Google Scholar
• Li AW, Wu QV, Warnick G, et al. The HAS-RISC score for Venous Thromboembolism (VTE) Risk Stratification in newly diagnosed multiple myeloma patients starting Immunomodulatory Drugs (IMID). In: editor. Blood. San Diego: ASH; 2018. p. 144.
   Google Scholar
• Zamagni E, Brioli A, Tacchetti P, et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost. 2011;37:209–219.
   PubMed Web of Science ®Google Scholar
• Carr ME Jr., Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med. 1996;128:83–88.
   PubMed Web of Science ®Google Scholar
• Carr ME Jr., Zekert SL. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol. 1994;266:H1195–H1201.
   PubMedGoogle Scholar
• Undas A, Zubkiewicz-Usnarska L, Helbig G, et al. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Blood Coagul Fibrinolysis. 2015;26:621–627.
   PubMed Web of Science ®Google Scholar
• Zangari M, Berno T, Zhan F, et al. Activated protein C resistance as measured by residual factor V after Russell‘s viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis. 2011;22:420–423.
   PubMed Web of Science ®Google Scholar
• Zangari M, Saghafifar F, Mehta P, et al. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003;29:275–282.
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol. 1996;51:319–323.
   PubMed Web of Science ®Google Scholar
• Yasin Z, Quick D, Thiagarajan P, et al. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol. 1999;62:99–102.
   PubMed Web of Science ®Google Scholar
• Gruber A, Blasko G, Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res. 1986;42:579–581.
   PubMed Web of Science ®Google Scholar
• Auwerda JJ, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011;105:14–20.
   PubMed Web of Science ®Google Scholar
• Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873–1880.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24(Suppl 1):S5–S11.
   PubMedGoogle Scholar
• Joseph L, Fink LM, Hauer-Jensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis. 2002;13:105–116.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kamphuisen PW, Meyer G, et al. Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial. J Clin Oncol. 2017;35:1078–1085.
   PubMed Web of Science ®Google Scholar
• Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84:345–349.
   PubMed Web of Science ®Google Scholar
• Yagci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol. 2003;74:231–237.
   PubMed Web of Science ®Google Scholar
• Minnema MC, Fijnheer R, De Groot PG, et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 2003;1:445–449.
   PubMed Web of Science ®Google Scholar
• Legendre P, Verstraete E, Martin M, et al. Hypocoagulability as assessed by thrombin generation test in newly-diagnosed patients with multiple myeloma. Blood Cells Mol Dis. 2017;66:47–49.
   PubMed Web of Science ®Google Scholar
• Bagratuni T, Kastritis E, Politou M, et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol. 2013;88:765–770.
   PubMed Web of Science ®Google Scholar
• Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112:2703–2708.
   PubMed Web of Science ®Google Scholar
• Leiba M, Malkiel S, Budnik I, et al. Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. Blood Cells Mol Dis. 2017;65:1–7.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012;3:255–266.
   PubMedGoogle Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Robak M, Trelinski J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol. 2012;29:3574–3580.
   PubMed Web of Science ®Google Scholar
• Abdullah WZ, Roshan TM, Hussin A, et al. Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. Blood Coagul Fibrinolysis. 2013;24:893–895.
   PubMed Web of Science ®Google Scholar
• Al-Ani F, Bermejo JM, Mateos MV, et al. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. Thromb Res. 2016;141:84–90.
   PubMed Web of Science ®Google Scholar
• Sanfilippo KML, Luo S, Carson KR, et al. Aspirin may be inadequate thromboprophylaxis in multiple myeloma. Blood. 2017;130:3419.
   Web of Science ®Google Scholar
• Swan D, Rocci A, Bradbury C, et al. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol. 2018;183:538–556.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615–624.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711–719.
   PubMed Web of Science ®Google Scholar
• Leleu X, Rodon P, Hulin C, et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost. 2013;110:844–851.
   PubMed Web of Science ®Google Scholar
• Park YPP, Poudel SK, Jia X, et al. Clinical outcomes with direct oral anticoagulants compared to low molecular weight heparins in the treatment of cancer-associated venous thromboembolism. Blood. 2018;132:1237.
   Google Scholar
• Man L, Morris A, Brown J, et al. Use of direct oral anticoagulants in patients on immunomodulatory agents. J Thromb Thrombolysis. 2017;44:298–302.
   PubMed Web of Science ®Google Scholar
• Storrar NPF, Mathur A, Johnson PRE, et al. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol. 2019;185:142–144.
   PubMed Web of Science ®Google Scholar
• Cornell RFG, Goldhaber SZ, Engelhardt BG, et al. Apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma receiving Immunomodulatory therapy. Front Oncol. 2019. doi: 10.3389/fonc.2019.00045
   Google Scholar
• Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–e66.
   PubMed Web of Science ®Google Scholar
• Frere C, Benzidia I, Marjanovic Z, et al. Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges. Cancers (Basel). 2019;10:11.
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Giustozzi M, Becattini C. Venous thromboembolism and cancer: current and future role of direct-acting oral anticoagulants. Thromb Res. 2019;177:33–41.
   PubMed Web of Science ®Google Scholar
• Lim MS, Enjeti AK. Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: report of 5 cases and literature review. Crit Rev Oncol Hematol. 2016;105:92–99.
   PubMed Web of Science ®Google Scholar
• Khanal N, Bociek RG, Chen B, et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol. 2016;91:E468–E72.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Saccullo G, Marietta M, et al. Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus. 2018;24:1–10.
   Google Scholar
• Riess H, Prandoni P, Harder S, et al. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions. Crit Rev Oncol Hematol. 2018;132:169–179.
   PubMed Web of Science ®Google Scholar
• Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19:82–93.
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Thomas-Schoemann A, Allard M, et al. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: clinical consequences. Crit Rev Oncol Hematol. 2018;129:102–112.
   PubMed Web of Science ®Google Scholar